SMMT news

Summit Therapeutics filed a Current Report on Form 8-K to include a legal opinion from counsel regarding the qualification of shares to be resold by a stockholder. This is a standard regulatory filing required to support a pending offering.

Summit Therapeutics amended its charter to increase the number of authorized shares of common stock to 2.0 billion from 1.0 billion, approved by stockholders on November 4, 2026. This increase provides greater flexibility for the company's financing and future execution of its strategic plans.

Summit Therapeutics announced updated overall survival results at WCLC 2026 for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, maintaining efficacy and safety profiles across regions.

Summit's partner Akeso announced Phase III data showing ivonescimab significantly improved survival over pembrolizumab in PD-L1 positive patients, prompting the company to proceed with the ongoing global HARMONi-7 study.

Summit partner Akeso announced positive overall survival results from the Phase III HARMONi-2 trial in NSCLC. Ivonescimab, licensed for Summit's territories as SMT112, showed statistically significant improvement over pembrolizumab for a key endpoint, reinforcing its potential commercial value.

Ivonescimab plus chemotherapy showed statistically significant overall survival superior to Durvalumab plus chemo in the advanced biliary tract cancer Phase III HARMONi-GI1 trial, a significant early-stage development for Summit's partner Akeso.

Summit Therapeutics announced the HARMONi-GU1 Phase II/III trial for ivonescimab in first-line bladder cancer. The study targets a major indication for ii antibodies in oncology.

Updated analysis of the global Phase III HARMONi trial demonstrates statistically significant and consistent overall survival benefits for ivonescimab plus chemotherapy in both Western and Asian NSCLC patients.

Summit Therapeutics presented Phase II data for ivonescimab combined with chemotherapy in first-line metastatic colorectal cancer, achieving a 70.8% objective response rate with manageable safety profile. The results support continued clinical development of the bispecific antibody candidate and com…